Electric aircraft developer Heart Aerospace raised $35m from investors including Mesa Air and United, while several corporates are set to exit remote access software developer Openpath.

GV has contributed to two rounds for the gene-editing technology developer, which publicly launched yesterday with $315m of funding.

Access Biotechnology helped the small molecule drug developer increase its total funding to over $300m in a round led by BVF Partners.

Tigermed and WuXi Biologics took part in the biopharmaceutical company's series D round, which will accelerate the development of its immuno-oncology drug candidates.

Existing investor Agilent helped the biomedical analysis technology developer close a series C round that pushed its overall funding past $110m.

Lilly Asia Ventures co-led a series A round for ProfoundBio that will help it develop its novel technology and targeted cancer therapeutics.

IP Group has returned for a series C round for the PNNL spinout, having already backed the series A and B rounds.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

Alphabet, GeneScience, AstraZeneca, Shire, Novartis, Ping An, KPC and Stevanato are in line for exits after the drug delivery technology developer filed to go public.

The Boston Scientific-backed medical device maker has filed to raise up to $100m in an offering on the Nasdaq Global Market.